Allogene Therapeutics, Inc. (ALLO)
Largest Insider Buys in Sector
ALLO Stock Price History Chart
ALLO Stock Performance
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Activity of Allogene Therapeutics, Inc.
Over the last 12 months, insiders at Allogene Therapeutics, Inc. have bought $5M and sold $158,820 worth of Allogene Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Allogene Therapeutics, Inc. have bought $6.97M and sold $28.82M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Belldegrun Arie (director) — $5M. Parker Geoffrey M. (CHIEF FINANCIAL OFFICER) — $2,049.
The last purchase of 1,724,137 shares for transaction amount of $5M was made by Belldegrun Arie (director) on 2024‑05‑16.
List of Insider Buy and Sell Transactions, Allogene Therapeutics, Inc.
| 2024-12-09 | Sale | director | 9,136 0.0042% | $2.18 | $19,916 | -5.73% | ||
| 2024-12-05 | Sale | director | 9,221 0.0044% | $2.16 | $19,917 | +2.34% | ||
| 2024-06-18 | Sale | director | 18,641 0.008% | $2.28 | $42,488 | +18.39% | ||
| 2024-05-30 | Sale | director | 11,200 0.0051% | $2.34 | $26,181 | +6.10% | ||
| 2024-05-16 | director | 1.72M 0.9747% | $2.90 | $5M | -13.50% | |||
| 2024-01-30 | CHIEF FINANCIAL OFFICER | 190 0.0001% | $3.60 | $683 | -21.93% | |||
| 2023-12-18 | Sale | director | 18,640 0.0103% | $2.70 | $50,317 | -0.69% | ||
| 2023-08-07 | Sale | director | 10,000 0.0069% | $4.29 | $42,855 | -25.59% | ||
| 2023-02-13 | Sale | General Counsel | 3,000 0.002% | $6.85 | $20,550 | -40.59% | ||
| 2023-01-17 | Sale | General Counsel | 3,000 0.0021% | $7.04 | $21,120 | -31.37% | ||
| 2022-12-15 | Sale | General Counsel | 5,602 0.0041% | $7.53 | $42,186 | -29.66% | ||
| 2022-08-11 | Sale | 15,000 0.0106% | $16.75 | $251,250 | -61.71% | |||
| 2022-08-02 | Sale | EVP of R&D and CMO | 2,000 0.0013% | $11.97 | $23,940 | -47.84% | ||
| 2022-07-05 | Sale | EVP of R&D and CMO | 2,000 0.0014% | $11.44 | $22,880 | -38.52% | ||
| 2022-06-22 | Sale | 10,000 0.0069% | $11.76 | $117,600 | -33.78% | |||
| 2022-06-21 | Sale | EVP of R&D and CMO | 2,000 0.0014% | $11.18 | $22,360 | -30.17% | ||
| 2022-05-19 | Sale | EVP of R&D and CMO | 11,500 0.0079% | $7.40 | $85,092 | +18.54% | ||
| 2022-03-15 | Sale | President and CEO | 23,648 0.0164% | $7.65 | $180,879 | +21.54% | ||
| 2022-03-15 | Sale | General Counsel | 8,849 0.0062% | $7.68 | $67,962 | +21.54% | ||
| 2022-03-15 | Sale | EVP of R&D and CMO | 5,169 0.0036% | $7.71 | $39,848 | +21.54% |
Insider Historical Profitability
| Belldegrun Arie | director | 1724137 0.8223% | $1.90 | 4 | 0 | <0.0001% |
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 819590 0.3909% | $1.90 | 1 | 0 | |
| Humer Franz B | director | 307507 0.1467% | $1.90 | 1 | 2 | +2.3% |
| MESSEMER DEBORAH M. | director | 157629 0.0752% | $1.90 | 0 | 3 | |
| PFIZER INC | 10 percent owner | 22032040 10.5079% | $1.90 | 1 | 0 | +2.3% |
| TPG Group Holdings (SBS) Advisors, Inc. | 10 percent owner | 18716306 8.9265% | $1.90 | 1 | 17 | +2.3% |
| Chang David D | President and CEO | 2289652 1.092% | $1.90 | 1 | 3 | +2.3% |
| Bhavnagri Veer | General Counsel | 577677 0.2755% | $1.90 | 0 | 16 | |
| Amado Rafael | EVP of R&D and CMO | 540257 0.2577% | $1.90 | 0 | 9 | |
| Kazam Joshua A | director | 258885 0.1235% | $1.90 | 1 | 0 | <0.0001% |
| WITTE OWEN N. | 218271 0.1041% | $1.90 | 1 | 5 | +2.3% | |
| MOORE ALISON | Chief Technical Officer | 120430 0.0574% | $1.90 | 0 | 14 | |
| SCHMIDT ERIC THOMAS | Chief Financial Officer | 100546 0.048% | $1.90 | 0 | 8 | |
| Mayo Stephen | director | 25328 0.0121% | $1.90 | 0 | 1 |
Institutional Investor Ownership
| Fidelity Investments | $113.38M | 12.17 | 25.36M | +0.48% | +$546,676.53 | 0.01 | |
| Tpg Gp A Llc | $83.66M | 8.98 | 18.72M | 0% | +$0 | 1.62 | |
| BlackRock | $43.15M | 4.63 | 9.65M | -3.49% | -$1.56M | <0.01 | |
| State Street | $41.05M | 4.41 | 9.18M | +278.37% | +$30.2M | <0.01 | |
| The Vanguard Group | $36.69M | 3.94 | 8.21M | -9.12% | -$3.68M | <0.01 | |
| PRIMECAP Management Co | $24.35M | 2.62 | 5.45M | +3.15% | +$744,254.99 | 0.02 | |
| JPMorgan Chase | $23.16M | 2.49 | 5.18M | -24.97% | -$7.71M | <0.01 | |
| T. Rowe Price | $18.68M | 2.01 | 4.18M | +76.16% | +$8.07M | <0.01 | |
| Boxer Capital, LLC | $17.21M | 1.85 | 3.85M | New | +$17.21M | 0.35 | |
| Citadel Advisors LLC | $13.92M | 1.49 | 3.11M | -23.19% | -$4.2M | 0.01 | |
| Frazier Life Sciences Management L P | $12.82M | 1.38 | 2.87M | New | +$12.82M | 0.58 | |
| Woodline Partners LP | $11.77M | 1.26 | 2.63M | +2.19% | +$252,447.73 | 0.1 | |
| Geode Capital Management | $10.6M | 1.14 | 2.37M | +1.55% | +$161,570.86 | <0.01 | |
| Morgan Stanley | $9.98M | 1.07 | 2.23M | +33.83% | +$2.52M | <0.01 | |
| Dimensional Fund Advisors | $9.13M | 0.98 | 2.04M | +33.11% | +$2.27M | <0.01 | |
| Wildcat Capital Management | $7.88M | 0.92 | 1.92M | 0% | +$0 | 2.86 | |
| Two Sigma | $8.54M | 0.92 | 1.91M | -17.42% | -$1.8M | 0.01 | |
| Vida Ventures Advisors Llc | $8.04M | 0.86 | 1.8M | 0% | +$0 | 4.47 | |
| Two Sigma Advisers LP | $5.95M | 0.64 | 1.33M | +4.18% | +$238,698.00 | 0.01 | |
| Goldman Sachs | $5.79M | 0.62 | 1.29M | -61.21% | -$9.13M | <0.01 | |
| Rafferty Asset Management Llc | $4.43M | 0.48 | 990,703 | +332.61% | +$3.4M | 0.01 | |
| Northern Trust | $4.34M | 0.47 | 971,067 | -4.27% | -$193,452.64 | <0.01 | |
| Charles Schwab | $3.84M | 0.41 | 858,476 | +17.14% | +$561,615.31 | <0.01 | |
| Nordea Investment Management Ab | $3.38M | 0.36 | 742,114 | +0.19% | +$6,518.20 | <0.01 | |
| Octagon Capital Advisors LP | $3.22M | 0.35 | 720,000 | New | +$3.22M | 0.02 | |
| Citigroup | $3.03M | 0.33 | 678,229 | +1,875.96% | +$2.88M | <0.01 | |
| UBS | $2.32M | 0.25 | 519,201 | +186.54% | +$1.51M | <0.01 | |
| Zacks Investment Management | $2.06M | 0.22 | 459,800 | +17.16% | +$301,085.64 | 0.02 | |
| Td Asset Management Inc | $1.96M | 0.21 | 437,436 | +83.92% | +$892,212.04 | <0.01 | |
| Caxton Associates | $1.93M | 0.21 | 431,186 | -44.37% | -$1.54M | 0.09 | |
| Cerity Partners | $1.9M | 0.2 | 424,169 | -18.05% | -$417,551.54 | 0.01 | |
| Coastal Bridge Advisors Llc | $1.82M | 0.2 | 406,847 | 0% | +$0 | 0.37 | |
| Bank of America | $1.81M | 0.19 | 404,382 | +22.21% | +$328,518.26 | <0.0001 | |
| Renaissance Technologies | $1.77M | 0.19 | 396,900 | -13.46% | -$275,991.31 | <0.01 | |
| Mirae Asset Global Investments Co Ltd | $1.77M | 0.17 | 361,913 | +85.14% | +$812,904.26 | <0.01 | |
| Nuveen | $1.35M | 0.15 | 302,255 | -15.47% | -$247,204.44 | <0.0001 | |
| BNY Mellon | $1.34M | 0.14 | 300,553 | -7.23% | -$104,723.09 | <0.0001 | |
| Susquehanna Fundamental Investments Llc | $1.28M | 0.14 | 286,408 | New | +$1.28M | 0.06 | |
| The Manufacturers Life Insurance Company | $1.26M | 0.14 | 282,150 | +37.48% | +$343,814.66 | <0.01 | |
| Mitsubishi UFJ Kokusai Asset Management | $972,203.00 | 0.1 | 217,495 | -1.63% | -$16,087.54 | <0.01 | |
| Swiss National Bank | $960,156.00 | 0.1 | 214,800 | 0% | +$0 | <0.01 | |
| Millennium Management LLC | $900,571.00 | 0.1 | 201,470 | -89.5% | -$7.68M | <0.01 | |
| Prudential Financial | $886,901.00 | 0.1 | 198,412 | -47.63% | -$806,512.58 | <0.01 | |
| D. E. Shaw & Co. | $875,127.00 | 0.09 | 195,778 | +158.83% | +$537,016.45 | <0.01 | |
| PDT Partners | $844,955.00 | 0.09 | 189,028 | +1,085.58% | +$773,685.33 | 0.06 | |
| Ameriprise Financial | $845,008.00 | 0.09 | 189,040 | -0.66% | -$5,609.85 | <0.0001 | |
| Ubs Asset Management Americas Inc | $761,184.00 | 0.08 | 170,287 | +8.66% | +$60,693.75 | <0.0001 | |
| ExodusPoint Capital Management, LP | $729,000.00 | 0.08 | 163,023 | -64.78% | -$1.34M | 0.01 | |
| Los Angeles Capital Management LLC | $717,985.00 | 0.08 | 160,623 | -3.23% | -$23,936.86 | <0.01 | |
| Barclays | $700,000.00 | 0.08 | 156,747 | -15.23% | -$125,756.79 | <0.0001 |